Literature DB >> 11695949

Maternal infections and subsequent psychosis among offspring.

S L Buka1, M T Tsuang, E F Torrey, M A Klebanoff, D Bernstein, R H Yolken.   

Abstract

BACKGROUND: We tested the hypothesis that maternal infections during pregnancy are associated with the subsequent development of schizophrenia and other psychoses in adulthood.
METHODS: We conducted a nested case-control study of 27 adults with schizophrenia and other psychotic illnesses and 54 matched unaffected control subjects (matched for sex, ethnicity, and date of birth) from the Providence, RI, cohort of the Collaborative Perinatal Project. We retrieved stored blood samples that had been obtained from these mothers at the end of pregnancy. These samples were analyzed for total class-specific immunoglobulins and for specific antibodies directed at recognized perinatal pathogens capable of affecting brain development.
RESULTS: Maternal levels of IgG and IgM class immunoglobulins before the mothers were delivered of their neonates were significantly elevated among the case series (t = 3.06, P =.003; t = 2.93, P =.004, respectively, for IgG and IgM immunoglobulin-albumin ratios). Secondary analyses indicated a significant association between maternal antibodies to herpes simplex virus type 2 glycoprotein gG2 and subsequent psychotic illness (matched t test = 2.43, P =.02). We did not find significant differences between case and control mothers in the serum levels of IgA class immunoglobulins, or in specific IgG antibodies to herpes simplex virus type 1, cytomegalovirus, Toxoplasma gondii, rubella virus, human parvovirus B19, Chlamydia trachomatis, or human papillomavirus type 16.
CONCLUSIONS: The offspring of mothers with elevated levels of total IgG and IgM immunoglobulins and antibodies to herpes simplex virus type 2 are at increased risk for the development of schizophrenia and other psychotic illnesses in adulthood.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11695949     DOI: 10.1001/archpsyc.58.11.1032

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  142 in total

Review 1.  Perinatal risk factors for schizophrenia: how specific are they?

Authors:  Hélène Verdoux
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

2.  Association between parental hospital-treated infection and the risk of schizophrenia in adolescence and early adulthood.

Authors:  Philip R Nielsen; Thomas M Laursen; Preben B Mortensen
Journal:  Schizophr Bull       Date:  2011-10-20       Impact factor: 9.306

Review 3.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

Review 4.  The role of obstetric events in schizophrenia.

Authors:  Mary Catherine Clarke; Michelle Harley; Mary Cannon
Journal:  Schizophr Bull       Date:  2005-11-23       Impact factor: 9.306

Review 5.  Schizophrenia: an update and review.

Authors:  Jehannine Austin
Journal:  J Genet Couns       Date:  2005-10       Impact factor: 2.537

6.  Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis.

Authors:  E Fuller Torrey; John J Bartko; Zhao-Rong Lun; Robert H Yolken
Journal:  Schizophr Bull       Date:  2006-11-03       Impact factor: 9.306

7.  Covariance modeling of MRI brain volumes in memory circuitry in schizophrenia: Sex differences are critical.

Authors:  Brandon Abbs; Lichen Liang; Nikos Makris; Ming Tsuang; Larry J Seidman; Jill M Goldstein
Journal:  Neuroimage       Date:  2011-04-08       Impact factor: 6.556

8.  Prenatal infection as a risk factor for schizophrenia.

Authors:  Alan S Brown
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

9.  Viral regulation of aquaporin 4, connexin 43, microcephalin and nucleolin.

Authors:  S Hossein Fatemi; Timothy D Folsom; Teri J Reutiman; Robert W Sidwell
Journal:  Schizophr Res       Date:  2007-11-09       Impact factor: 4.939

Review 10.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.